Endovascular Engineering raises $80M in Series C funding led by Gilde Healthcare and Norwest to commercialize its Hēlo Thrombectomy Platform for pulmonary embolism treatment.
Amount Raised
$80 Million
Round Type
Series C
Menlo ParkBiotechnologyHealth CareMedical Devicemedical devicesInvestors
Description
Endovascular Engineering, Inc. (E2), a Menlo Park, CA-based commercial-stage medical technology company, raised $80M in Series C funding. The round was led by Gilde Healthcare and Norwest, with participation from existing investors including Santé Ventures, 415 Capital, S3 Ventures, Panakès Partners, M&L Healthcare Investments, as well as two strategic investors. The funds will support commercialization of its new Hēlo Thrombectomy Platform for treating pulmonary embolism
Quick answer
Endovascular Engineering raised $80 Million in a Series C round, dated April 7, 2026. Investors: Norwest Venture Partners, S3 Ventures, 415 Capital, Panakès Partners, M&L Healthcare Investments, Santé Ventures and Gilde Healthcare. Endovascular Engineering is based in Menlo Park, California, United States.
- How much did Endovascular Engineering raise?
- Endovascular Engineering raised $80 Million in a Series C round on April 7, 2026.
- Who invested in Endovascular Engineering?
- Norwest Venture Partners, S3 Ventures, 415 Capital, Panakès Partners, M&L Healthcare Investments, Santé Ventures and Gilde Healthcare are named as investors in this round.
- What does Endovascular Engineering do?
- Endovascular Engineering, Inc. ("E2") is at the forefront of transforming venous thromboembolism (VTE) treatment with the Hēlo™ Thrombectomy System, a novel technology designed for the treatment of pulmonary embolism.
- Where is Endovascular Engineering based and how big is it?
- Endovascular Engineering is based in Menlo Park, California, United States. Fundz records about 37 employees.
- Who are the decision-makers at Endovascular Engineering?
- Fundz holds 1 contact at Endovascular Engineering. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Medical Device and medical devices around the same time
Companies in the same sectors as Endovascular Engineering that raised within 45 days of this round, from Fundz verified event records.
- IceCure Medical raised $4M on March 26, 2026.
- Neurosoft Bioelectronics raised $7.5M (Seed) on May 20, 2026.
- Garland Surgical Ltd raised $4.1M (Seed) on May 19, 2026.
- NinaMED raised $14M on May 18, 2026.
- Vortex Imaging raised $12M (Funding Round) on May 18, 2026.
- Butterfly Medical Ltd raised $21M (Series C) on May 14, 2026.
Who to call at Endovascular Engineering, and when
A new round usually means Endovascular Engineering is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Endovascular Engineering raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Endovascular Engineering, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Endovascular Engineering. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Endovascular Engineering raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Endovascular Engineering raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.